How plausible is the use of dietary n-3 PUFA in the adjuvant therapy of cancer?

Nutrition Research Reviews

Volumn 29, Issue 1, 2016, Pages 102-125

  Serini, Simona ^a   Ottes Vasconcelos, Renata ^b   Fasano, Elena ^a   Calviello, Gabriella ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b FEDERAL UNIVERSITY OF RIO GRANDE   (Brazil)

Author keywords

Antineoplastic drugs; Combinations; Human trials; n 3 PUFA; Preclinical studies

Indexed keywords

1,4 PHENYLENEBIS(METHYLENE)SELENOCYANATE; ANTINEOPLASTIC AGENT; CELECOXIB; CISPLATIN; DOCETAXEL; DOCOSAHEXAENOIC ACID; DOXORUBICIN; ETOPOSIDE; FISH OIL; FLUOROURACIL; HYPERICIN; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; OXALIPLATIN; PACLITAXEL; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER CELL LINE; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER PREVENTION; CHEMICAL CARCINOGENESIS; COLON CANCER; DIET THERAPY; DRUG CYTOTOXICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LYMPHOMA CELL; MYELOMA CELL; NONHUMAN; PROSTATE CANCER CELL LINE; REVIEW; SYSTEMATIC REVIEW; ADJUVANT CHEMORADIOTHERAPY; DIET; FAT INTAKE; MULTIMODALITY CANCER THERAPY; NEOPLASM; SEA FOOD;

ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DIET; DIETARY FATS; FATTY ACIDS, OMEGA-3; HUMANS; NEOPLASMS; SEAFOOD;

EID: 84973882630     PISSN: 09544224     EISSN: 14752700     Source Type: Journal    
DOI: 10.1017/S0954422416000044     Document Type: Review

References (170)

1. Cicero AF, Reggi A, Parini A, et al. (2012) Application of polyunsaturated fatty acids in internal medicine: beyond the established cardiovascular effects. Arch Med Sci 8, 784-793.
2. Wendel M & Heller AR (2009) Anticancer actions of omega-3 fatty acids: current state and future perspectives. Anticancer Agents Med Chem 9, 457-470.
3. Deckelbaum RJ & Torrejon C (2012) The omega-3 fatty acid nutritional landscape: health benefits and sources. J Nutr 142, 587S-591S.
4. Anti M, Marra G, Armelao F, et al. (1992) Effect of omega-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer. Gastroenterology 103, 883-891.
5. Anti M, Armelao F, Marra G, et al. (1994) Effects of different doses of fish oil on rectal cell proliferation in patients with sporadic colonic adenomas. Gastroenterology 107, 1709-1718.
6. Palozza P, Anti M, Franceschelli P, et al. (1995) Modulation of vitamin E level as a possible mechanism of the antiproliferative effect of n-3 PUFA. In Oxygen Paradox, pp. 653-664 [KJA Davies and F Ursini, editors]. Padova: CLEUP University Press.
7. Calviello G, Palozza P, Piccioni E, et al. (1998) Dietary supplementation with eicosapentaenoic and docosahexaenoic acid inhibits growth of Morris hepatocarcinoma 3924A in rats: effects on proliferation and apoptosis. Int J Cancer 75, 699-705.
8. Calviello G, Palozza P, Franceschelli P, et al. (1999) Eicosapentaenoic acid inhibits the growth of liver preneoplastic lesions and alters membrane phospholipid composition and peroxisomal β-oxidation. Nutr Cancer 34, 206-212.
9. Calviello G, Palozza P, Di Nicuolo F, et al. (2000) n-3 PUFA dietary supplementation inhibits proliferation and storeoperated calcium influx in thymoma cells growing in Balb/c mice. J Lipid Res 41, 182-189.
10. Vecchini A, Ceccarelli V, Susta F, et al. (2004) Dietary α-linolenic acid reduces COX-2 expression and induces apoptosis of hepatoma cells. J Lipid Res 45, 308-316.
11. 2 induced ERK-1 and -2 and HIF-1α induction pathway. Carcinogenesis 25, 2303-2310.
12. Calviello G, Di Nicuolo F, Serini S, et al. (2005) Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5-fluorouracil. Cancer Chemother Pharmacol 55, 12-20.
13. Calviello G, Resci F, Serini S, et al. (2007) Docosahexaenoic acid induces proteasome-dependent degradation of β-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2. Carcinogenesis 28, 1202-1209.
14. Serini S, Trombino S, Oliva F, et al. (2008) Docosahexaenoic acid induces apoptosis in lung cancer cells by increasing MKP-1 and down-regulating p-ERK1/2 and p-p38 expression. Apoptosis 13, 1172-1183.
15. Serini S, Fasano E, Piccioni E, et al. (2012) DHA induces apoptosis and differentiation in human melanoma cells in vitro: involvement of HuR-mediated COX-2 mRNA stabilization and β-catenin nuclear translocation. Carcinogenesis 33, 164-173.
16. Fasano E, Serini S, Piccioni E, et al. (2012) DHA induces apoptosis by altering the expression and cellular location of GRP78 in colon cancer cell lines. Biochim Biophys Acta 1822, 1762-1772.
17. Calviello G, Serini S & Piccioni E (2007) n-3 Polyunsaturated fatty acids and the prevention of colorectal cancer: molecular mechanisms involved. Curr Med Chem 14, 3059-3069.
18. Serini S, Piccioni E, Merendino N, et al. (2009) Dietary polyunsaturated fatty acids as inducers of apoptosis: implications for cancer. Apoptosis 14, 135-152.
19. Hu Y, Sun H, Owens RT, et al. (2010) Syndecan-1-dependent suppression of PDK1/Akt/Bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer. Neoplasia 12, 826-836.
20. Notarnicola M, Messa C, Refolo MG, et al. (2011) Polyunsaturated fatty acids reduce fatty acid synthase and hydroxy-methyl-glutaryl CoA-reductase gene expression and promote apoptosis in HepG2 cell line. Lipids Health Dis 10, 10.
21. Sun H, Hu Y, Gu Z, et al. (2011) Omega-3 fatty acids induce apoptosis in human breast cancer cells and mouse mammary tissue through syndecan-1 inhibition of the MEKErk pathway. Carcinogenesis 32, 1518-1524.
22. Ma DW, Seo J, Switzer KC, et al. (2004) n-3 PUFA and membrane microdomains: a new frontier in bioactive lipid research. J Nutr Biochem 15, 700-706.
23. Hardman WE (2002) Omega-3 fatty acids to augment cancer therapy. J Nutr 132, Suppl. 11, 3508S-3512S.
24. Serhan CN (2005) Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins. Curr Opin Clin Nutr Metab Care 8, 115-121.
25. Serhan CN, Clish CB, Brannon J, et al. (2000) Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192, 1197-1204.
26. Marcheselli VL, Hong S, Lukiw WJ, et al. (2003) Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 278, 43807-43817.
27. Mukherjee PK, Marcheselli VL, Serhan CN, et al. (2004) Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A 101, 8491-8496.
28. Gonda TA, Tu S & Wang TC (2009) Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle 8, 2005-2013.
29. Serini S, Fasano E, Piccioni E, et al. (2011) Dietary n-3 polyunsaturated fatty acids and the paradox of their health benefits and potential harmful effects. Chem Res Toxicol 24, 2093-2105.
30. Mazière C, Conte MA, Degonville J, et al. (1999) Cellular enrichment with polyunsaturated fatty acids induces an oxidative stress and activates the transcription factors AP1 and NFκB. Biochem Biophys Res Commun 265, 116-122.
31. Ding WQ, Vaught JL, Yamauchi H, et al. (2004) Differential sensitivity of cancer cells to docosahexaenoic acid-induced cytotoxicity: the potential importance of down-regulation of superoxide dismutase 1 expression. Mol Cancer Ther 3, 1109-1117.
32. Colquhoun A & Schumacher RI (2001) γ-Linolenic acid and eicosapentaenoic acid induce modifications in mitochondrial metabolism, reactive oxygen species generation, lipid peroxidation and apoptosis in Walker 256 rat carcinosarcoma cells. Biochim Biophys Acta 1533, 207-219.
33. Germain E, Lavandier F, Chajès V, et al. (1999) Dietary n-3 polyunsaturated fatty acids and oxidants increase rat mammary tumor sensitivity to epirubicin without change in cardiac toxicity. Lipids 34, Suppl. 1, S203.
34. Gleissman H, Yang R, Martinod K, et al. (2010) Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates. FASEB J 24, 906-915.
35. Calviello G, Serini S & Palozza P (2006) n-3 Polyunsaturated fatty acids as signal transduction modulators and therapeutical agents in cancer. Curr Signal Transd Ther 1, 255-271.
36. Calviello G, Su HM, Weylandt KH, et al. (2013) Experimental evidence of ω-3 polyunsaturated fatty acid modulation of inflammatory cytokines and bioactive lipid mediators: their potential role in inflammatory, neurodegenerative, and neoplastic diseases. Biomed Res Int 2013, 743171.
37. Calviello G, Serini S, Piccioni E, et al. (2009) Antineoplastic effects of n-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: preventive and therapeutic strategies. Nutr Cancer 61, 287-301.
38. Song F, Parekh S, Hooper L, et al. (2010) Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess 14, 1-193.
39. Granci V, Cai F, Lecumberri E, et al. (2013) Colon cancer cell chemosensitisation by fish oil emulsion involves apoptotic mitochondria pathway. Br J Nutr 109, 1188-1195.
40. Jordan A & Stein J (2003) Effect of an omega-3 fatty acid containing lipid emulsion alone and in combination with 5-fluorouracil (5-FU) on growth of the colon cancer cell line Caco-2. Eur J Nutr 42, 324-331.
41. De Carlo F, Witte TR, Hardman WE, et al. (2013) Omega-3 eicosapentaenoic acid decreases CD133 colon cancer stem-like cell marker expression while increasing sensitivity to chemotherapy. PLOS ONE 8, e69760.
42. Presnell SC, Petersen B & Heidaran M (2002) Stem cells in adult tissues. Semin Cell Dev Biol 13, 369-376.
43. Reya T, Morrison SJ, Clarke MF, et al. (2001) Stem cells, cancer, and cancer stem cells. Nature 414, 105-111.
44. Vasudevan A, Yu Y, Banerjee S, et al. (2014) Omega-3 fatty acid is a potential preventive agent for recurrent colon cancer. Cancer Prev Res (Phila) 7, 1138-1148.
45. El-Bayoumy K, Rao CV & Reddy BS (2001) Multiorgan sensitivity to anticarcinogenesis by the organoselenium 1,4-phenylenebis(methylene)selenocyanate. Nutr Cancer 40, 18-27.
46. Narayanan BA, Narayanan NK, Desai D, et al. (2004) Effects of a combination of docosahexaenoic acid and 1,4-phenylene bis(methylene) selenocyanate on cyclooxygenase 2, inducible nitric oxide synthase and β-catenin pathways in colon cancer cells. Carcinogenesis 25, 2443-2449.
47. Vaculová A, Hofmanová J, Andera L, et al. (2005) TRAIL and docosahexaenoic acid cooperate to induce HT-29 colon cancer cell death. Cancer Lett 229, 43-48.
48. Skender B, Hofmanová J, Slavík J, et al. (2014) DHAmediated enhancement of TRAIL-induced apoptosis in colon cancer cells is associated with engagement of mitochondria and specific alterations in sphingolipid metabolism. Biochim Biophys Acta 1841, 1308-1317.
49. Nagane M, Huang HJ & Cavenee WK (2001) The potential of TRAIL for cancer chemotherapy. Apoptosis 6, 191-197.
50. Zhang XD, Nguyen T, Thomas WD, et al. (2000) Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. Fed Eur Biochem Soc Lett 482, 193-199.
51. Refaat A, Abd-Rabou A & Reda A (2014) TRAIL combinations: the new 'trail' for cancer therapy. Oncol Lett 7, 1327-1332.
52. L. Cancer Res 62, 1583-1587.
53. L: differential impact on TRAIL resistance in Bax-deficient carcinoma. J Cell Biol 188, 851-862.
54. Kello M, Mikes J, Jendzelovský R, et al. (2010) PUFAs enhance oxidative stress and apoptosis in tumour cells exposed to hypericin-mediated PDT. Photochem Photobiol Sci 9, 1244-1251.
55. Kumamoto-Yonezawa Y, Sasaki R, Suzuki Y, et al. (2010) Enhancement of human cancer cell radiosensitivity by conjugated eicosapentaenoic acid: a mammalian DNA polymerase inhibitor. Int J Oncol 36, 577-584.
56. Cai F, Sorg O, Granci V, et al. (2014) Interaction of ω-3 polyunsaturated fatty acids with radiation therapy in two different colorectal cancer cell lines. Clin Nutr 33, 164-170.
57. Manda K, Kriesen S, Hildebrandt G, et al. (2011) Omega-3 fatty acid supplementation in cancer therapy: does eicosapentanoic acid influence the radiosensitivity of tumor cells? Strahlenther Onkol 187, 127-134.
58. Lim SJ, Lee E, Lee EH, et al. (2012) Docosahexaenoic acid sensitizes colon cancer cells to sulindac sulfide-induced apoptosis. Oncol Rep 27, 2023-2030.
59. Shi J, He Q, An J, et al. (2009) Sulindac sulfide differentially induces apoptosis in Smac-proficient and -deficient human colon cancer cells. Mol Cell Pharmacol 1, 92-97.
60. Kuan CY, Walker TH, Luo PG, et al. (2011) Long-chain polyunsaturated fatty acids promote paclitaxel cytotoxicity via inhibition of the MDR1 gene in the human colon cancer Caco-2 cell line. J Am Coll Nutr 30, 265-273.
61. Ullah MF (2008) Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac J Cancer Prev 9, 1-6.
62. Szakács G, Paterson JK, Ludwig JA, et al. (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5, 219-234.
63. Bacso Z, Nagy H, Goda K, et al. (2004) Raft and cytoskeleton associations of an ABC transporter: P-glycoprotein. Cytometry A 61, 105-116.
64. Storch CH, Ehehalt R, Haefeli WE, et al. (2007) Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J Pharmacol Exp Ther 323, 257-264.
65. Klappe K, Hinrichs JW, Kroesen BJ, et al. (2004) MRP1 and glucosylceramide are co-ordinately over expressed and enriched in rafts during multidrug resistance acquisition in colon cancer cells. Int J Cancer 110, 511-522.
66. Gelsomino G, Corsetto PA, Campia I, et al. (2013) Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition. Mol Cancer 12, 137.
67. Germain E, Chajès V, Cognault S, et al. (1998) Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MDA-MB-231: relationship to lipid peroxidation. Int J Cancer 75, 578-583.
68. Mahéo K, Vibet S, Steghens JP, et al. (2005) Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation. Free Radic Biol Med 39, 742-751.
69. Vibet S, Goupille C, Bougnoux P, et al. (2008) Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines through loss of glutathione peroxidase (GPx1) response. Free Radic Biol Med 44, 1483-1491.
70. Menendez JA, Lupu R & Colomer R (2005) Exogenous supplementation with ω-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. Eur J Cancer Prev 14, 263-270.
71. - breast cancer cells. Lipids 47, 1019-1030.
72. Meshkini A & Yazdanparast R (2012) Involvement of oxidative stress in taxol-induced apoptosis in chronic myelogenous leukemia K562 cells. Exp Toxicol Pathol 64, 357-365.
73. Wirtitsch M, Roth E, Bachleitner-Hofmann T, et al. (2009) Omega-3 and omega-6 polyunsaturated fatty acids enhance arsenic trioxide efficacy in arsenic trioxide-resistant leukemic and solid tumor cells. Oncol Res 18, 83-94.
74. Siddiqui RA, Zerouga M, Wu M, et al. (2005) Anticancer properties of propofol-docosahexaenoate and propofoleicosapentaenoate on breast cancer cells. Breast Cancer Res 7, R645-R654.
75. Mammoto T, Mukai M, Mammoto A, et al. (2002) Intravenous anesthetic, propofol inhibits invasion of cancer cells. Cancer Lett 184, 165-170.
76. Tsuchiya M, Asada A, Arita K, et al. (2002) Induction and mechanism of apoptotic cell death by propofol in HL-60 cells. Acta Anaesthesiol Scand 46, 1068-1074.
77. Siddiqui RA, Harvey KA, Xu Z, et al. (2014) Characterization of lovastatin-docosahexaenoate anticancer properties against breast cancer cells. Bioorg Med Chem 22, 1899-1908.
78. Goldstein JL & Brown MS (1990) Regulation of the mevalonate pathway. Nature 343, 425-430.
79. Kusama T, Mukai M, Iwasaki T, et al. (2001) Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Cancer Res 61, 4885-4891.
80. Dimitroulakos J, Ye LY, Benzaquen M, et al. (2001) Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 7, 158-167.
81. Collisson EA, Kleer C, Wu M, et al. (2003) Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther 2, 941-948.
82. Wei N, Mi MT & Zhou Y (2007) Influences of lovastatin on membrane ion flow and intracellular signaling in breast cancer cells. Cell Mol Biol Lett 12, 1-15.
83. Kang S, Kim ES & Moon A (2009) Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras. Oncol Rep 21, 1317-1322.
84. Klawitter J, Shokati T & Moll V (2010) Effects of lovastatin on breast cancer cells: a proteo-metabonomic study. Breast Cancer Res 12, R16.
85. Narayanan NK, Narayanan BA & Reddy BS (2005) A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-κB, and steroid hormone receptors. Int J Oncol 26, 785-792.
86. Narayanan NK, Narayanan BA, Bosland M, et al. (2006) Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells. Int J Cancer 119, 1586-1598.
87. Wang MH, Grossmann ME & Young CY (2004) Forced expression of heatshock protein 70 increases the secretion of Hsp70 and provides protection against tumour growth. Br J Cancer 90, 926-931.
88. Lipinski KS, Pelech S, Mountain A, et al. (2006) Nitroreductasebased therapy of prostate cancer, enhanced by raising expression of heat shock protein 70, acts through increased anti-tumour immunity. Cancer Immunol Immunother 55, 347-354.
89. Shaikh IA, Brown I, Schofield AC, et al. (2008) Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-κB pathway. Prostate 68, 1635-1646.
90. Petrylak DP (2006) The treatment of hormone-refractory prostate cancer: docetaxel and beyond. Rev Urol 8, S48-S55.
91. Collins R, Trowman R, Norman G, et al. (2006) A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. Br J Cancer 95, 457-462.
92. Yared JA & Tkaczuk KH (2012) Update on taxane development: new analogs and new formulations. Drug Des Devel Ther 6, 371-384.
93. Sturlan S, Baumgartner M, Roth E, et al. (2003) Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells. Blood 101, 4990-4997.
94. Chou WC & Dang CV (2005) Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. Curr Opin Hematol 12, 1-6.
95. Brown M, Bellon M & Nicot C (2007) Emodin and DHA potently increase arsenic trioxide interferon-α-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1. Blood 109, 1653-1659.
96. Guffy MM, North JA & Burns CP (1984) Effect of cellular fatty acid alteration on adriamycin sensitivity in cultured L1210 murine leukemia cells. Cancer Res 44, 1863-1866.
97. Zerouga M, Stillwell W & Jenski LJ (2002) Synthesis of a novel phosphatidylcholine conjugated to docosahexaenoic acid and methotrexate that inhibits cell proliferation. Anticancer Drugs 13, 301-311.
98. de Lima TM, Amarante-Mendes GP & Curi R (2007) Docosahexaenoic acid enhances the toxic effect of imatinib on Bcr-Abl expressing HL-60 cells. Toxicol In Vitro 21, 1678-1685.
99. Kinsella JE & Black JM (1993) Effects of polyunsaturated fatty acids on the efficacy of antineoplastic agents toward L5178Y lymphoma cells. Biochem Pharmacol 45, 1881-1887.
100. Fahrmann JF & Hardman WE (2013) Omega 3 fatty acids increase the chemo-sensitivity of B-CLL-derived cell lines EHEB and MEC-2 and of B-PLL-derived cell line JVM-2 to anti-cancer drugs doxorubicin, vincristine and fludarabine. Lipids Health Dis 12, 36.
101. Cui ZG, Piao JL, Kondo T, et al. (2014) Molecular mechanisms of hyperthermia-induced apoptosis enhanced by docosahexaenoic acid: implication for cancer therapy. Chem Biol Interact 215, 46-53.
102. Overgaard J (1989) The current and potential role of hyperthermia in radiotherapy. Int J Radiat Oncol Biol Phys 16, 535-549.
103. Abdi J, Garssen J, Faber J, et al. (2014) Omega-3 fatty acids, EPA and DHA induce apoptosis and enhance drug sensitivity in multiple myeloma cells but not in normal peripheral mononuclear cells. J Nutr Biochem 25, 1254-1262.
104. Markovina S, Callander NS, O'Connor SL, et al. (2008) Bortezomib-resistant nuclear factor-κB activity in multiple myeloma cells. Mol Cancer Res 6, 1356-1364.
105. Ri M, Iida S, Nakashima T, et al. (2010) Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 24, 1506-1512.
106. Hideshima T, Chauhan D, Richardson P, et al. (2002) NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 277, 16639-16647.
107. Patterson WL 3rd & Georgel PT (2014) Breaking the cycle: the role of omega-3 polyunsaturated fatty acids in inflammation-driven cancers. Biochem Cell Biol 92, 321-328.
108. Ikushima S, Fujiwara F, Todo S, et al. (1991) Effects of polyunsaturated fatty acids on vincristine-resistance in human neuroblastoma cells. Anticancer Res 11, 1215-1220.
109. Lindskog M, Gleissman H, Ponthan F, et al. (2006) Neuroblastoma cell death in response to docosahexaenoic acid: sensitization to chemotherapy and arsenic-induced oxidative stress. Int J Cancer 118, 2584-2593.
110. Rudra PK & Krokan HE (2001) Cell-specific enhancement of doxorubicin toxicity in human tumour cells by docosahexaenoic acid. Anticancer Res 21, 29-38.
111. Wang F, Bhat K, Doucette M, et al. (2011) Docosahexaenoic acid (DHA) sensitizes brain tumor cells to etoposide-induced apoptosis. Curr Mol Med 11, 503-511.
112. Manda K, Kriesen S, Hildebrandt G, et al. (2011) Omega-3 fatty acid supplementation in cancer therapy: does eicosapentanoic acid influence the radiosensitivity of tumor cells? Strahlenther Onkol 187, 127-134.
113. Chiu LC, Tong KF & Ooi VE (2005) Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells. Biomed Pharmacother 59, S293-S297.
114. Zhuo Z, Zhang L, Mu Q, et al. (2009) The effect of combination treatment with docosahexaenoic acid and 5-fluorouracil on the mRNA expression of apoptosis-related genes, including the novel gene BCL2L12, in gastric cancer cells. In Vitro Cell Dev Biol Anim 45, 69-74.
115. Hardman WE, Barnes CJ, Knight CW, et al. (1997) Effects of iron supplementation and ET-18-OCH3 on MDA-MB 231 breast carcinomas in nude mice consuming a fish oil diet. Br J Cancer 76, 347-354.
116. Hardman WE, Avula CP, Fernandes G, et al. (2001) Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer xenografts. Clin Cancer Res 7, 2041-2049.
117. Shao Y, Pardini L & Pardini RS (1995) Dietary menhaden oil enhances mitomycin C antitumor activity toward human mammary carcinoma MX-1. Lipids 30, 1035-1045.
118. Hardman WE, Moyer MP & Cameron IL (1999) Fish oil supplementation enhanced CPT-11 (Irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side effects. Br J Cancer 81, 440-448.
119. Huan M, Cui H, Teng Z, et al. (2012) In vivo anti-tumor activity of a new doxorubicin conjugate via α-linolenic acid. Biosci Biotechnol Biochem 76, 1577-1579.
120. Shao Y, Pardini L & Pardini RS (1997) Intervention of transplantable human mammary carcinoma MX-1 chemotherapy with dietary menhaden oil in athymic mice: increased therapeutic effects and decreased toxicity of cyclophosphamide. Nutr Cancer 28, 63-73.
121. Hardman WE, Moyer MP & Cameron IL (2002) Consumption of an omega-3 fatty acids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan) in mice. Br J Cancer 86, 983-988.
122. Germain E, Lavandier F, Chajès V, et al. (1999) Dietary n-3 polyunsaturated fatty acids and oxidants increase rat mammary tumor sensitivity to epirubicin without change in cardiac toxicity. Lipids 34, Suppl. 1, S203.
123. Huan M, Cui H, Teng Z, et al. (2012) In vivo anti-tumor activity of a new doxorubicin conjugate via α-linolenic acid. Biosci Biotechnol Biochem 76, 1577-1579.
124. Wynter MP, Russell ST & Tisdale MJ (2004) Effect of n-3 fatty acids on the antitumour effects of cytotoxic drugs. In Vivo 18, 543-547.
125. Hardman WE, Moyer MP & Cameron IL (2000) Dietary fish oil sensitizes A549 lung xenografts to doxorubicin chemotherapy. Cancer Lett 151, 145-151.
126. Cha MC, Meckling KA & Stewart C (2002) Dietary docosahexaenoic acid levels influence the outcome of arabinosylcytosine chemotherapy in L1210 leukemic mice. Nutr Cancer 44, 176-181.
127. Xue H, Le Roy S, Sawyer MB, et al. (2009) Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colon tumour. Br J Nutr 102, 434-442.
128. Yam D, Peled A & Shinitzky M (2001) Suppression of tumor growth and metastasis by dietary fish oil combined with vitamins E and C and cisplatin. Cancer Chemother Pharmacol 47, 34-40.
129. Kimura Y, Takaku T, Nakajima S, et al. (2001) Effects of carp and tuna oils on 5-fluorouracil-induced antitumor activity and side effects in sarcoma 180-bearing mice. Lipids 36, 353-359.
130. Barnés CM, Prox D, Christison-Lagay EA, et al. (2012) Inhibition of neuroblastoma cell proliferation with omega-3 fatty acids and treatment of a murine model of human neuroblastoma using a diet enriched with omega-3 fatty acids in combination with sunitinib. Pediatr Res 71, 168-178.
131. Bradley MO, Webb NL, Anthony FH, et al. (2001) Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 7, 3229-3238.
132. Wang Y, Li L, Jiang W, et al. (2005) Synthesis and evaluation of a DHA and 10-hydroxycamptothecin conjugate. Bioorg Med Chem 13, 5592-5599.
133. Colas S, Mahéo K, Denis F, et al. (2006) Sensitization by dietary docosahexaenoic acid of rat mammary carcinoma to anthracycline: a role for tumor vascularization. Clin Cancer Res 12, 5879-5886.
134. Manni A, Xu H, Washington S, et al. (2010) The impact of fish oil on the chemopreventive efficacy of tamoxifen against development of N-methyl-N-nitrosourea-induced rat mammary carcinogenesis. Cancer Prev Res (Phila) 3, 322-330.
135. Colas S, Paon L, Denis F, et al. (2004) Enhanced radiosensitivity of rat autochthonous mammary tumors by dietary docosahexaenoic acid. Int J Cancer 109, 449-454.
136. Hajjaji N, Besson P & Bougnoux P (2012) Tumor and non-tumor tissues differential oxidative stress response to supplemental DHA and chemotherapy in rats. Cancer Chemother Pharmacol 70, 17-23.
137. Manni A, Richie JP Jr, Xu H, et al. (2011) Effects of fish oil and Tamoxifen on preneoplastic lesion development and biomarkers of oxidative stress in the early stages of N-methyl-Nnitrosourea-induced rat mammary carcinogenesis. Int J Oncol 39, 1153-1164.
138. United States Environmental Proctection Agency (1988) Recommendations for and documentation of biological values for use in risk assessment (EPA/600/6-87/008). http://www.tera.org/Tools/ratmousevalues.pdf (accessed December 2014).
139. Hajjaji N, Couet C, Besson P, et al. (2012) DHA effect on chemotherapy-induced body weight loss: an exploratory study in a rodent model of mammary tumors. Nutr Cancer 64, 1000-1007.
140. Fasano E, Serini S, Cittadini A, et al. (2015) Long-chain n-3 PUFA against breast and prostate cancer: which are the appropriate doses for intervention studies in animals and humans? Crit Rev Food Sci Nutr (epublication ahead of print version 21 April 2015).
141. Serini S, Innocenti I, Piccioni E, et al. (2010) The effects of omega-3 polyunsaturated fatty acids against cancer. In Vitamins in the Prevention of Human Diseases, pp. 679-696 [W Hermann and R Obei, editors]. Berlin: De Gruyter.
142. Calviello G & Serini S (2010) Introduction: omega-3 PUFAs, why are we speaking of them? In Dietary Omega-3 Polyunsaturated Fatty Acids and Cancer, pp. ix-xxi [G Calviello and S Serini, editors]. Dordrecht: Springer.
143. van der Meij BS, Langius JA, Smit EF, et al. (2010) Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment. J Nutr 140, 1774-1780.
144. Finocchiaro C, Segre O, Fadda M, et al. (2012) Effect of n-3 fatty acids on patients with advanced lung cancer: a doubleblind, placebo-controlled study. Br J Nutr 108, 327-333.
145. Murphy RA, Mourtzakis M, Chu QS, et al. (2011) Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 117, 1775-1782.
146. Murphy RA, Mourtzakis M, Chu QS, et al. (2011) Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced non-small cell lung cancer. Cancer 117, 3774-3780.
147. Trabal J, Leyes P, Forga M, et al. (2010) Potential usefulness of an EPA-enriched nutritional supplement on chemotherapy tolerability in cancer patients without overt malnutrition. Nutr Hosp 25, 736-740.
148. Bonatto SJ, Oliveira HH, Nunes EA, et al. (2012) Fish oil supplementation improves neutrophil function during cancer chemotherapy. Lipids 47, 383-389.
149. Mocellin MC, Pastore e Silva Jde A, Camargo Cde Q, et al. (2013) Fish oil decreases C-reactive protein/albumin ratio improving nutritional prognosis and plasma fatty acid profile in colorectal cancer patients. Lipids 48, 879-888.
150. Szkaradkiewicz A, Marciniak R, Chudzicka-Strugała I, et al. (2009) Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients. Arch Immunol Ther Exp (Warsz) 57, 291-294.
151. Chung YC & Chang YF (2003) Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. Eur J Gastroenterol Hepatol 15, 369-373.
152. Sunpaweravong S, Puttawibul P, Ruangsin S, et al. (2014) Randomized study of antiinflammatory and immunemodulatory effects of enteral immunonutrition during concurrent chemoradiotherapy for esophageal cancer. Nutr Cancer 66, 1-5.
153. Bougnoux P, Hajjaji N, Ferrasson MN, et al. (2009) Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer 101, 1978-1985.
154. Ghoreishi Z, Esfahani A, Djazayeri A, et al. (2012) Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer 12, 355.
155. Chaudhry V, Rowinsky EK, Sartorius SE, et al. (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35, 304-311.
156. Hutchins-Wiese HL, Picho K, Watkins BA, et al. (2014) High-dose eicosapentaenoic acid and docosahexaenoic acid supplementation reduces bone resorption in postmenopausal breast cancer survivors on aromatase inhibitors: a pilot study. Nutr Cancer 66, 68-76.
157. Santen RJ (2011) Clinical review: effect of endocrine therapies on bone in breast cancer patients. J Clin Endocrinol Metab 96, 308-319.
158. Arshad A, Chung WY, Steward W, et al. (2013) Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil. HPB (Oxford) 15, 428-432.
159. Rahbari NN, Reissfelder C, Mühlbayer M, et al. (2011) Correlation of circulating angiogenic factors with circulating tumor cells and disease recurrence in patients undergoing curative resection for colorectal liver metastases. Ann Surg Oncol 18, 2182-2191.
160. Fietkau R, Lewitzki V, Kuhnt T, et al. (2013) A diseasespecific enteral nutrition formula improves nutritional status and functional performance in patients with head and neck and esophageal cancer undergoing chemoradiotherapy: results of a randomized, controlled, multicenter trial. Cancer 119, 3343-3353.
161. Bükki J, Stanga Z, Tellez FB, et al. (2013) Omega-3 poly-unsaturated fatty acids for the prevention of severe neutropenic enterocolitis in patients with acute myeloid leukemia. Nutr Cancer 65, 834-842.
162. Wolff AC, Donehower RC, Carducci MK, et al. (2003) Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 9, 3589-3597.
163. Fracasso PM, Picus J, Wildi JD, et al. (2009) Phase 1 and pharmacokinetic study of weekly docosahexaenoic acidpaclitaxel, Taxoprexin, in resistant solid tumor malignancies. Cancer Chemother Pharmacol 63, 451-458.
164. Payne M, Ellis P, Dunlop D, et al. (2006) DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II openlabel multicenter trial. J Thorac Oncol 1, 984-990.
165. Jones RJ, Hawkins RE, Eatock MM, et al. (2008) A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother Pharmacol 61, 435-441.
166. Homsi J, Bedikian AY, Kim KB, et al. (2009) Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res 19, 238-242.
167. Bedikian AY, DeConti RC, Conry R, et al. (2011) Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol 22, 787-793.
168. Homsi J, Bedikian AY, Papadopoulos NE, et al. (2010) Phase 2 open-label study of weekly docosahexaenoic acidpaclitaxel in patients with metastatic uveal melanoma. Melanoma Res 20, 507-510.
169. Thornton E, Howard SA, Jagannathan J, et al. (2012) Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients. Br J Radiol 85, 1420-1426.
170. Ederhy S, Izzedine H, Massard C, et al. (2011) Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol 80, 369-379.